Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Genmab Reaches Analyst Target Price

In recent trading, shares of Genmab A/S (Symbol: GMAB) have crossed above the average analyst 12-month target price of $43.85, changing hands for $44.69/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation

We haven't written up this one. Nasdaq Markets has the full story — the link below goes straight to it.

Also reported by 1 other outlet

Read the original at nasdaq.com →

More in Finance & Markets

Add Up The Parts: SNAV Could Be Worth $43

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price…

More from Tuesday 27 October →